Abstract
Major depressive disorder (MDD) is one of the most common psychiatric illnesses worldwide, with reported prevalence rates ranging between 10% and 19%. Pharmacotherapy is a first-line option for the management of MDD and, as a result, the use of antidepressants has increased 4 fold in the last 20 years. Serotonin is the most commonly dysregulated neurotransmitter in the etiology of MDD and this system is the primary focus of most medications used in the treatment of illness. Although antidepressant use in adults increases the risk of developing new onset type 2 diabetes, the mechanisms underlying this association are poorly defined. This review will focus on 1) the evidence from human and animal studies suggesting a link between the use of antidepressants that target serotonin signaling (i.e., SSRIs, serotonin-norepinephrine reuptake inhibitors (SNRIs), serotonin antagonist and reuptake inhibitors (SARIs), and noradrenergic and specific serotonergic antidepressants (NaSSAs)) and increased risk of diabetes, and 2) the mechanisms by which alterations in serotonin signalling by antidepressants can affect glucose homeostasis.
Keywords: Antidepressants, insulin, noradrenergic and specific serotonergic antidepressants selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, serotonin antagonist and reuptake inhibitors, type 2 diabetes.
Current Diabetes Reviews
Title:Major Depressive Disorder and Diabetes: Does Serotonin Bridge the Gap?
Volume: 11 Issue: 2
Author(s): Nicole E. De Long, Rebecca A. Stepita, Valerie H. Taylor and Alison C. Holloway
Affiliation:
Keywords: Antidepressants, insulin, noradrenergic and specific serotonergic antidepressants selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, serotonin antagonist and reuptake inhibitors, type 2 diabetes.
Abstract: Major depressive disorder (MDD) is one of the most common psychiatric illnesses worldwide, with reported prevalence rates ranging between 10% and 19%. Pharmacotherapy is a first-line option for the management of MDD and, as a result, the use of antidepressants has increased 4 fold in the last 20 years. Serotonin is the most commonly dysregulated neurotransmitter in the etiology of MDD and this system is the primary focus of most medications used in the treatment of illness. Although antidepressant use in adults increases the risk of developing new onset type 2 diabetes, the mechanisms underlying this association are poorly defined. This review will focus on 1) the evidence from human and animal studies suggesting a link between the use of antidepressants that target serotonin signaling (i.e., SSRIs, serotonin-norepinephrine reuptake inhibitors (SNRIs), serotonin antagonist and reuptake inhibitors (SARIs), and noradrenergic and specific serotonergic antidepressants (NaSSAs)) and increased risk of diabetes, and 2) the mechanisms by which alterations in serotonin signalling by antidepressants can affect glucose homeostasis.
Export Options
About this article
Cite this article as:
Long E. De Nicole, Stepita A. Rebecca, Taylor H. Valerie and Holloway C. Alison, Major Depressive Disorder and Diabetes: Does Serotonin Bridge the Gap?, Current Diabetes Reviews 2015; 11 (2) . https://dx.doi.org/10.2174/1573399811666150223123053
DOI https://dx.doi.org/10.2174/1573399811666150223123053 |
Print ISSN 1573-3998 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6417 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cultured Adult Animal Neurons and Schwann Cells Give Us New Insights into Diabetic Neuropathy
Current Diabetes Reviews Metallothionein is a Potential Therapeutic Strategy for Amyotrophic Lateral Sclerosis
Current Pharmaceutical Design Future Treatment for COPD: Targeting Oxidative Stress and its Related Signal
Recent Patents on Inflammation & Allergy Drug Discovery Calcium Homeostasis Following Traumatic Neuronal Injury
Current Neurovascular Research Muscle Atrophy Classification: The Need for a Pathway-Driven Approach
Current Pharmaceutical Design Cell Based-Gene Delivery Approaches for the Treatment of Spinal Cord Injury and Neurodegenerative Disorders
Current Stem Cell Research & Therapy Angiotensin I-Converting Enzyme: A Pathogenetic Role in Diabetic Renal Damage?
Current Diabetes Reviews Deciphering the Role of Aberrant Protein Post-Translational Modification in the Pathology of Neurodegeneration
CNS & Neurological Disorders - Drug Targets The Impact of Pregnancy and Parity on Type 1 Diabetes Complications
Current Diabetes Reviews Gene Transfer to the Central Nervous System: Current State of the Art of the Viral Vectors
Current Genomics Prion-like Mechanisms in Alzheimer's Disease
Current Alzheimer Research Water and Ion Channels: Crucial in the Initiation and Progression of Apoptosis in Central Nervous System?
Current Neuropharmacology 11C-verapamil to Assess P-gp Function in Human Brain During Aging,Depression and Neurodegenerative Disease
Current Topics in Medicinal Chemistry NAD Metabolism and Functions: A Common Therapeutic Target for Neoplastic, Metabolic and Neurodegenerative Diseases
Current Topics in Medicinal Chemistry Contribution of Spinal Cord Oligodendrocytes to Neuroinflammatory Diseases and Pain
Current Medicinal Chemistry The Role of Biomarkers to Diagnose Diabetic Foot Osteomyelitis. A Meta-analysis
Current Diabetes Reviews Promotion of Apoptosis in Cancer Cells by Selective Purine-Derived Pharmacological CDK Inhibitors: One Outcome, Many Mechanisms
Current Pharmaceutical Design Free Radicals in Diseases and Potential Role of Phytoconstituents-A Cause with Emerging Importance
Current Chemical Biology Identification of Pharmacological Targets in Amyotrophic Lateral Sclerosis Through Genomic Analysis of Deregulated Genes and Pathways
Current Genomics Impact of Diabetes in Blood-Testis and Blood-Brain Barriers: Resemblances and Differences
Current Diabetes Reviews